{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:16:35Z","timestamp":1792401395307,"version":"4.4.0"},"reference-count":290,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Although the discovery and characterization of multiple tumor antigens have sparked the development of many antigen\/derived cancer vaccines, many are poorly immunogenic and thus, lack clinical efficacy. Adjuvants are therefore incorporated into vaccine formulations to trigger strong and long-lasting immune responses. Adjuvants have generally been classified into two categories: those that \u2018depot\u2019 antigens (e.g. mineral salts such as aluminum hydroxide, emulsions, liposomes) and those that act as immunostimulants (Toll Like Receptor agonists, saponins, cytokines). In addition, several novel technologies using vector-based delivery of antigens have been used. Unfortunately, the immune system declines with age, a phenomenon known as immunosenescence, and this is characterized by functional changes in both innate and adaptive cellular immunity systems as well as in lymph node architecture. While many of the immune functions decline over time, others paradoxically increase. Indeed, aging is known to be associated with a low level of chronic inflammation\u2014inflamm-aging. Given that the median age of cancer diagnosis is 66 years and that immunotherapeutic interventions such as cancer vaccines are currently given in combination with or after other forms of treatments which themselves have immune-modulating potential such as surgery, chemotherapy and radiotherapy, the choice of adjuvants requires careful consideration in order to achieve the maximum immune response in a compromised environment. In addition, more clinical trials need to be performed to carefully assess how less conventional form of immune adjuvants, such as exercise, diet and psychological care which have all be shown to influence immune responses can be incorporated to improve the efficacy of cancer vaccines. In this review, adjuvants will be discussed with respect to the above-mentioned important elements.<\/jats:p>","DOI":"10.3389\/fimmu.2020.615240","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T06:21:55Z","timestamp":1613802115000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":112,"title":["Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments"],"prefix":"10.3389","volume":"11","author":[{"given":"Stefania","family":"Cuzzubbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mangsbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Nagarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinana","family":"Habra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan Graham","family":"Pockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie E. B.","family":"McArdle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.0500","article-title":"Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and\/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697)","volume":"33","author":"Lawson","year":"2015","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30254-7","article-title":"MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Dreno","year":"2018","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"A","DOI":"10.1200\/jco.2008.26.15_suppl.9004","article-title":"EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. [Abstract]","volume":"26","author":"Eggermont","year":"2008","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3182380f56","article-title":"Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma","volume":"255","author":"Hoshimoto","year":"2012","journal-title":"Ann Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1245\/s10434-017-6072-3","article-title":"Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases","volume":"24","author":"Faries","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000138","article-title":"Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL","volume":"39","author":"Engelstein","year":"2016","journal-title":"J Immunother"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0052","article-title":"Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival","volume":"2","author":"Carson","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.011","article-title":"Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer","volume":"23","author":"Butts","year":"2005","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial","volume":"15","author":"Butts","year":"2014","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0855","article-title":"A phase III clinical trial of the epidermal growth factor vaccine CIMAvax-EGF as switch maintenance therapy in advanced non-small cell lung cancer patients","volume":"22","author":"Rodriguez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.5335","article-title":"Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer","volume":"24","author":"Nemunaitis","year":"2006","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.035","article-title":"A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer","volume":"51","author":"Giaccone","year":"2015","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70259-5","article-title":"Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial","volume":"12","author":"Quoix","year":"2011","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00483-0","article-title":"TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b\/3 trial","volume":"17","author":"Quoix","year":"2016","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0274-x","article-title":"Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC","volume":"70","author":"Tosch","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1674","article-title":"A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small lung cancer patients","volume":"20","author":"Alfonso","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.17.186","article-title":"Phase III study of adjuvant vaccination with Bec2\/bacille Calmette\u2013Guerin in responding patients with limited-disease small-cell lung cancer (European organisation for research and treatment of cancer 08971-08971B; silva study)","volume":"23","author":"Giaccone","year":"2005","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.06.036","article-title":"Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2\/BCG in responding patients with limited disease small-cell lung cancer","volume":"44","author":"Bottomley","year":"2008","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immuno-therapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3223","article-title":"Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer","volume":"17","author":"Beer","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.05.024","article-title":"A randomized trial of radical radiotherapy for the management of pT1G3 NXM0 transitional cell carcinoma of the bladder","volume":"178","author":"Harland","year":"2007","journal-title":"J Urol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.11.031","article-title":"NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Gu\u00e9rin therapy for bladder cancer","volume":"59","author":"Chiong","year":"2011","journal-title":"Eur Urol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70236-0","article-title":"Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial","volume":"15","author":"Middleton","year":"2014","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11605-012-2064-6","article-title":"Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study","volume":"17","author":"Hardacre","year":"2013","journal-title":"J Gastrointest Surg"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.7.4.543","article-title":"PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma","volume":"7","author":"Madan","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.3005","article-title":"Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma","volume":"29","author":"Schuster","year":"2011","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/13928","article-title":"Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma","volume":"5","author":"Bendandi","year":"1999","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8903","article-title":"Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma","volume":"27","author":"Freedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181bfcea1","article-title":"A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma","volume":"33","author":"Ko\u00e7","year":"2010","journal-title":"J Immunother"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.9273","article-title":"Active idiotypic vaccination versus control immunotherapy for follicular lymphoma","volume":"32","author":"Levy","year":"2014","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12967-018-1507-6","article-title":"First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma","volume":"16","author":"Liau","year":"2018","journal-title":"J Transl Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2867","article-title":"Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial","volume":"25","author":"Mittendorf","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0307","article-title":"Phase III multicenter clinical trial of Sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer patients","volume":"16","author":"Miles","year":"2011","journal-title":"Oncologist"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.7150\/jca.7028","article-title":"Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial","volume":"4","author":"Ibrahim","year":"2013","journal-title":"J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60697-2","article-title":"An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial","volume":"372","author":"Wood","year":"2008","journal-title":"Lancet"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30408-9","article-title":"IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"17","author":"Rini","year":"2016","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh220","article-title":"Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01","volume":"96","author":"Smith","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.4057","article-title":"Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO\u2013the MIMOSA study","volume":"31","author":"Sabbatini","year":"2013","journal-title":"J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.05.006","article-title":"Vaccines, adjuvants and dendritic cells activators \u2013 Current status and future challenges","volume":"42","author":"Obeid","year":"2015","journal-title":"Semin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1434000","article-title":"Current challenges for cancer adjuvant development","volume":"17","author":"Bowen","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29847","article-title":"Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination","volume":"10","author":"Fernandez","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7803091","article-title":"Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment","volume":"7803091","author":"Flores -Borja","year":"2016","journal-title":"J Immunol Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.semcancer.2015.07.004","article-title":"Microenvironment abnormalities and lymphomagenesis: Immunological aspects","volume":"34","author":"Taylor","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-015-0140-7","article-title":"Sipuleucel-T (Provenge(\u00ae))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention","volume":"29","author":"Jaros\u0142awski","year":"2015","journal-title":"BioDrugs"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1006500107","article-title":"Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses","volume":"107","author":"Welters","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging. An evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8426874","article-title":"An update on inflamm-aging: mechanisms, prevention, and treatment","volume":"2016","author":"Xia","year":"2016","journal-title":"J Immunol Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2019.110632","article-title":"Immunosenescence: A systems-level overview of immune cell biology and strategies for improving vaccine responses","volume":"124","author":"Crooke","year":"2019","journal-title":"Exp Gerontol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.7774\/cevr.2015.4.1.54","article-title":"Vaccine adjuvant materials for cancer immunotherapy and control of infectious disease","volume":"4","author":"Lim","year":"2015","journal-title":"Clin Exp Vaccine Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/s1359-6446(03)02864-2","article-title":"Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity","volume":"8","author":"Marciani","year":"2003","journal-title":"Drug Discovery Today"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1459394","article-title":"Adjuvants: classification, modus operandi, and licensing","volume":"2016","author":"De Souza Apostolico","year":"2016","journal-title":"J\u00a0Immunol Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.132","article-title":"An RNA toolbox for cancer immunotherapy","volume":"17","author":"Pastor","year":"2018","journal-title":"Nat Rev Drug Discovery"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1172\/JCI11696","article-title":"IFN-gamma-dependent transcription of MHC class II IA is impaired in macrophages from aged mice","volume":"107","author":"Herrero","year":"2001","journal-title":"J Clin Invest"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/s0531-5565(01)00205-4","article-title":"Immunosenescence of macrophages: reduced MHC class II gene expression","volume":"37","author":"Herrero","year":"2002","journal-title":"Exper Gerontol"},{"key":"B68","first-page":"85","article-title":"Changes in the expression of HLA-class II antigens on peripheral blood monocytes from aged humans","volume":"8","author":"Villanueva","year":"1990","journal-title":"Dis Markers"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-010-9191-3","article-title":"Age-associated impaired plasmacytoid dendritic cell functions lead to decreased CD4 and CD8 T cell immunity","volume":"33","author":"Sridharan","year":"2011","journal-title":"Age (Dordr)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-010-9448-8","article-title":"Gupta S.Impaired functions of peripheral blood monocyte subpopulations in aged humans","volume":"30","author":"Nyugen","year":"2010","journal-title":"J Clin Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.2.970","article-title":"Age-associated defect in human TLR-1\/2 function","volume":"178","author":"van Duin","year":"2007","journal-title":"J Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500046","article-title":"Naive T cell maintenance and function in human aging","volume":"194","author":"Goronzy","year":"2015","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nri2318","article-title":"Ageing and life-long maintenance of T cell subsets in the face of latent persistent infections","volume":"8","author":"Nikolich-Zugich","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2010.09.010","article-title":"Role of CMV in immune senescence","volume":"157","author":"Pawelec","year":"2011","journal-title":"Virus Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301721","article-title":"Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans","volume":"192","author":"Wertheimer","year":"2014","journal-title":"J Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.4110\/in.2015.15.4.186","article-title":"Cytomegalovirus infection and memory T cell inflation","volume":"15","author":"Kim","year":"2015","journal-title":"Immune Netw"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1002\/art.21353","article-title":"Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis","volume":"52","author":"Bryl","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2012.04.003","article-title":"Signaling pathways in aged T cells - a reflection of T cell differentiation, cell senescence and host environment","volume":"24","author":"Goronzy","year":"2012","journal-title":"Semin Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M402194200","article-title":"Tumor necrosis factor-alpha and CD80 modulate CD28 expression through a similar mechanism of T cell receptor-independent inhibition of transcription","volume":"279","author":"Lewis","year":"2004","journal-title":"J Biol Chem"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.24.12182-12187.2001","article-title":"Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals","volume":"75","author":"Goronzy","year":"2001","journal-title":"J Virol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00107","article-title":"When aging reaches CD4+ T cells: phenotypic and functional changes","volume":"4","author":"Moro-Garcia","year":"2013","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.8.3539","article-title":"Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity","volume":"90","author":"Dranoff","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1860-3","article-title":"Systematic review of the use of granulocyte-macrophage colony- stimulating factor in patients with advanced melanoma","volume":"65","author":"Hoeller","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2883","article-title":"Multipeptide immune response to cancer vaccine IMA901 after single- dose cyclophosphamide associates with longer patient survival","volume":"18","author":"Walter","year":"2012","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/cncr.11045","article-title":"Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma","volume":"97","author":"Weber","year":"2003","journal-title":"Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1544","article-title":"Effect of granulocyte\/macrophage colony-stimulating factor on circulating CD8 + and CD4 + T cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial","volume":"15","author":"Slingluff","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181e311ac","article-title":"Immunogenicity for CD8+ and CD4+ T cells of two formulations of an incomplete Freund\u2019s adjuvant for multipeptide melanoma vaccines","volume":"33","author":"Slingluff","year":"2010","journal-title":"J Immunother"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1540","article-title":"Effect of granulocyte\/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine","volume":"15","author":"Faries","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl158","article-title":"Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients","volume":"18","author":"Parmiani","year":"2007","journal-title":"Ann Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial","volume":"312","author":"Hodi","year":"2014","journal-title":"JAMA"},{"key":"B91","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrc2541","article-title":"Toll-like receptors and cancer","volume":"9","author":"Rakoff-Nahoum","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.6.675","article-title":"The application of Toll like receptors for cancer therapy","volume":"6","author":"So","year":"2010","journal-title":"Int J Biol Sci"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2010.06.004","article-title":"Impact of aging on dendritic cell functions in humans","volume":"10","author":"Agrawal","year":"2011","journal-title":"Ageing Res Rev"},{"key":"B94","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1186\/s12885-019-5725-y","article-title":"Vaccination with synthetic long peptide formulated with CpG in an oil-in-water emulsion induces robust E7-specific CD8 T cell responses and TC-1 tumor eradication","volume":"19","author":"Maynard","year":"2019","journal-title":"BMC Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1172\/JCI23373","article-title":"Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909","volume":"115","author":"Speiser","year":"2005","journal-title":"J Clin Invest"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1216290","article-title":"Vaccination of stage III\/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T cell responses with multiple specificities including a novel DR7-restricted epitope","volume":"5","author":"Baumgaertner","year":"2016","journal-title":"Oncoimmunology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrd3203","article-title":"Targeting Toll-like receptors: emerging therapeutics","volume":"9","author":"Hennessy","year":"2010","journal-title":"Nat Rev Drug Discovery"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3892\/ijo_00000080","article-title":"Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-\u03baB activation and apoptosis","volume":"33","author":"Yoneda","year":"2008","journal-title":"Int J Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.10.6065","article-title":"Toll-like receptor ligands directly promote activated CD4+ T cell survival","volume":"172","author":"Gelman","year":"2004","journal-title":"J Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.7.3863","article-title":"Critical roles of myeloid differentiation factor 88-dependent proinflammatory cytokine release in early phase clearance of Listeria monocytogenes in mice","volume":"169","author":"Seki","year":"2002","journal-title":"J Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.3.1551","article-title":"Direct stimulation of human T cells via TLR5 and TLR7\/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells","volume":"175","author":"Caron","year":"2005","journal-title":"J Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.08.023","article-title":"The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation","volume":"25","author":"Gelman","year":"2006","journal-title":"Immunity"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2006.12.007","article-title":"CpG DNA inhibits CD4+CD25+ Treg suppression through direct MyD88-dependent costimulation of effector CD4+ T cells","volume":"108","author":"LaRosa","year":"2007","journal-title":"Immunol Lett"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210908","article-title":"Role of Toll-like receptors in gastrointestinal malignancies","volume":"27","author":"Fukata","year":"2008","journal-title":"Oncogene"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.1012501","article-title":"TLR agonists: our best frenemy in cancer immunotherapy","volume":"93","author":"Kaczanowska","year":"2013","journal-title":"J Leukoc Biol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36551","article-title":"Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance","volume":"120","author":"Cherfils-Vicini","year":"2010","journal-title":"J Clin Invest"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2011.07.307","article-title":"Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk","volume":"72","author":"Kutikhin","year":"2011","journal-title":"Hum Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22584","article-title":"Toll-like receptor 3 stimulation triggers metabolic reprogramming in pharyngeal cancer cell line through Myc, MAPK, and HIF","volume":"56","author":"Matijevic Glavan","year":"2017","journal-title":"Mol Carcinog"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1993","article-title":"Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth","volume":"71","author":"Cai","year":"2011","journal-title":"Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.03041.x","article-title":"Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas","volume":"128","author":"Rydberg","year":"2009","journal-title":"Immunology"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.04.022","article-title":"Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer","volume":"135","author":"Rhee","year":"2008","journal-title":"Gastroenterology"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijmm.2005.02.009","article-title":"Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori","volume":"295","author":"Schmausser","year":"2005","journal-title":"Int J Med Microbiol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019614","article-title":"Induction of TLR-2 and TLR-5 expression by Helicobacter pylori switches cagPAI-dependent signalling leading to the secretion of IL-8 and TNF-\u03b1","volume":"6","author":"Kumar","year":"2011","journal-title":"PloS One"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/716564","article-title":"Expression of Toll-like receptors on breast tumors: taking a toll on tumor microenvironment","volume":"2021","author":"Bhattacharya","year":"2012","journal-title":"Int J Breast Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2012.1374","article-title":"Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis","volume":"40","author":"Samara","year":"2012","journal-title":"Int J Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3892\/ijo_00000730","article-title":"Functional cell surface expression of Toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas","volume":"37","author":"Tanaka","year":"2010","journal-title":"Int J Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/pros.20710","article-title":"The Toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells","volume":"68","author":"Kundu","year":"2008","journal-title":"Prostate"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-415","article-title":"TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients","volume":"10","author":"Wang","year":"2010","journal-title":"BMC Cancer"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1251","article-title":"Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma","volume":"70","author":"Brignole","year":"2010","journal-title":"Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1007\/s13277-012-0416-1","article-title":"CpG ODN107 potentiates radiosensitivity of human glioma cells via TLR9-mediated NF-\u03baB activation and NO production","volume":"33","author":"Li","year":"2012","journal-title":"Tumour Biol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nop047","article-title":"Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study","volume":"12","author":"Carpentier","year":"2010","journal-title":"Neuro Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.12.003","article-title":"Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study","volume":"73","author":"Ursu","year":"2017","journal-title":"Eur J Cancer"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.18","article-title":"Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer","volume":"10","author":"Ragupathi","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.683011","article-title":"Identification of QS-21 as an inflammasome-activating molecular component of saponin adjuvants","volume":"291","author":"Marty-Roix","year":"2016","journal-title":"J Biol Chem"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0403572101","article-title":"Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans","volume":"101","author":"Davis","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00008","article-title":"Vaccine strategies to improve anti-cancer cellular immune responses","volume":"10","author":"Vermaelen","year":"2019","journal-title":"Front Immunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41467-017-00573-w","article-title":"Signalling strength determines proapoptotic functions of STING","volume":"8","author":"Gulen","year":"2017","journal-title":"Nat Commun"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1172\/JCI79915","article-title":"Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants","volume":"125","author":"Hanson","year":"2015","journal-title":"J Clin Invest"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0123","article-title":"STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer","volume":"2","author":"Chandra","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00406","article-title":"Mechanism of immunopotentiation and safety of aluminum adjuvants","volume":"3","author":"Hogenesch","year":"2012","journal-title":"Front Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1038\/nature06939","article-title":"Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants","volume":"453","author":"Eisenbarth","year":"2008","journal-title":"Nature"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.6.3755","article-title":"Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome","volume":"181","author":"Kool","year":"2008","journal-title":"J Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1104588108","article-title":"Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells","volume":"108","author":"MacLeod","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"B134","doi-asserted-by":"publisher","first-page":"S0168","DOI":"10.1016\/j.jconrel.2020.07.008","article-title":"Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination","volume":"10","author":"Gan","year":"2020","journal-title":"J Control Release"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1021\/nn404211j","article-title":"Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles","volume":"7","author":"Sun","year":"2013","journal-title":"ACS Nano"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8010128","article-title":"Better adjuvants for better vaccines: progress in adjuvant delivery systems, modifications, and adjuvant-antigen codelivery","volume":"8","author":"Wang","year":"2020","journal-title":"Vaccines"},{"key":"B137","doi-asserted-by":"publisher","first-page":"2666.7","DOI":"10.1016\/s0264-410x(00)00498-9","article-title":"Adjuvants designed for veterinary and human vaccines","volume":"19","author":"Aucouturier","year":"2001","journal-title":"Vaccine"},{"key":"B138","doi-asserted-by":"publisher","first-page":"111.8","DOI":"10.1586\/14760584.1.1.111","article-title":"Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines","volume":"1","author":"Aucouturier","year":"2002","journal-title":"Expert Rev Vaccines"},{"key":"B139","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1111\/j.1349-7006.2010.01653.x","article-title":"Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination","volume":"101","author":"Iseki","year":"2010","journal-title":"Cancer Sci"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1071455","article-title":"Safety and tolerability evaluation of the use of Montanide ISA\u212251 as vaccine adjuvant: A systematic review","volume":"12","author":"van Doorn","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"B141","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/1078-0432.CCR-14-1790","article-title":"Induction of robust type-I CD8+ T cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC","volume":"21","author":"Okada","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1097\/CJI.0000000000000017","article-title":"Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen","volume":"37","author":"Wada","year":"2014","journal-title":"J Immunother"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1640-x","article-title":"A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent\/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)","volume":"64","author":"Zandberg","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B144","article-title":"Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes","volume":"7","author":"Slingluff","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2468","article-title":"Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma","volume":"21","author":"Gibney","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.8.5033","article-title":"CD8+ CTL priming by exact peptide epitopes in incomplete Freund\u2019s adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity","volume":"179","author":"Bijker","year":"2007","journal-title":"J Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3105","article-title":"Persistent antigen at vaccination sites induces tumor-specific CD8+T cell sequestration, dysfunction and deletion","volume":"19","author":"Hailemichael","year":"2013","journal-title":"Nat Med"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-79","article-title":"Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: A histologic and immunophenotypic analysis","volume":"8","author":"Schaefer","year":"2010","journal-title":"J Transl Med"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1435-5","article-title":"Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund\u2019s adjuvant, with or without peptide","volume":"62","author":"Salerno","year":"2013","journal-title":"Cancer Immunol Immunothe"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0929-7","article-title":"Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with Montanide ISA51 and CpG7909","volume":"60","author":"Kuball","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.03.093","article-title":"Safety of MF59 adjuvant","volume":"26","author":"Schultze","year":"2008","journal-title":"Vaccine"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2014.06.027","article-title":"Designing and building the next generation of improved vaccine adjuvants","volume":"190","author":"Brito","year":"2014","journal-title":"J Control Release"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2012.05.003","article-title":"MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice","volume":"13","author":"Yang","year":"2012","journal-title":"Int Immunopharmacol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-3","article-title":"Improvement of different vaccine delivery systems for cancer therapy","volume":"10","author":"Bolhassani","year":"2011","journal-title":"Mol Cancer"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxw015","article-title":"Vaccine adjuvants as potential cancer immunotherapeutics","volume":"28","author":"Temizoz","year":"2016","journal-title":"Int Immunol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.apsb.2018.06.005","article-title":"Adapting liposomes for oral drug delivery","volume":"9","author":"He","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S125866","article-title":"Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens","volume":"12","author":"Gao","year":"2017","journal-title":"Int J Nanomed"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1177\/2051013614541440","article-title":"Liposomes as vaccine delivery systems: a review of the recent advances","volume":"2","author":"Schwendener","year":"2014","journal-title":"Ther Adv Vaccines"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1186\/1477-3155-12-17","article-title":"A nanoliposome delivery system to synergistically trigger TLR4 AND TLR7","volume":"12","author":"Fox","year":"2014","journal-title":"J\u00a0Nanobiotechnol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2010.07.053","article-title":"A novel liposomal vaccine improves humoral immunity and prevents tumor pulmonary metastasis in mice","volume":"399","author":"Zhong","year":"2010","journal-title":"Int J Pharm"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.07.004","article-title":"The nanoparticulation by octaarginine-modified liposome improves \u03b1-galactosylceramide-mediated antitumor therapy via systemic administration","volume":"171","author":"Nakamura","year":"2013","journal-title":"J Control Release"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S186606","article-title":"A peptide-CpG-DNA-liposome complex vaccine targeting TM4SF5 suppresses growth of pancreatic cancer in a mouse allograft model","volume":"11","author":"Park","year":"2018","journal-title":"OncoTargets Ther"},{"key":"B163","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.canlet.2014.09.016","article-title":"P5 HER2\/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer","volume":"355","author":"Shariat","year":"2014","journal-title":"Cancer Lett"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2019.10.002","article-title":"Intranasal administration of miR-146a agomir rescued the pathological process and cognitive impairment in an AD Mouse Model","volume":"18","author":"Mai","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.9b00489","article-title":"Codelivery of mRNA with \u03b1-galactosylceramide using a new lipopolyplex formulation induces a strong antitumor response upon intravenous administration","volume":"4","author":"Guevara","year":"2019","journal-title":"ACS Omega"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-011-1003-3","article-title":"Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): Phase IIB randomized, multicenter, open-label trial","volume":"137","author":"Butts","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7111","article-title":"Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: Results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma","volume":"31","author":"Kruit","year":"2013","journal-title":"J Clin Oncol"},{"key":"B168","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1186\/s12885-018-5193-9","article-title":"A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma","volume":"18","author":"McQuade","year":"2018","journal-title":"BMC Cancer"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1071","article-title":"Human Autologous Tumor-Specific T cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen","volume":"10","author":"Neelapu","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1026529","article-title":"Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients","volume":"4","author":"Berinstein","year":"2015","journal-title":"Oncoimmunology"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-156","article-title":"First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients","volume":"10","author":"Berinstein","year":"2012","journal-title":"J Transl Med"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4. 5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.070771","article-title":"Human papillomavirus vaccines launch a new era in cervical cancer prevention","volume":"177","author":"Dawar","year":"2007","journal-title":"CMAJ"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.6.11.1113","article-title":"Clinical applications of virosomes in cancer immunotherapy","volume":"6","author":"Adamina","year":"2006","journal-title":"Expert Opin Biol Ther"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/08923973.2014.971963","article-title":"Cancer vaccine adjuvants - - recent clinical progress and future perspectives","volume":"37","author":"Banday","year":"2015","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B176","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4161\/hv.2.1.2494","article-title":"Applications of influenza virosomes as a delivery system","volume":"2","author":"Cusi","year":"2006","journal-title":"Hum Vaccin"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0666-9","article-title":"A virosomal formulated Her-2\/neu multi-peptide vaccine induces Her-2\/neu-specific immune responses in patients with metastatic breast cancer: A phase I study","volume":"119","author":"Wiedermann","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"B178","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-013-2410-8","article-title":"Vaccination for the prevention and treatment of breast cancer with special focus on Her-2\/neu peptide vaccines","volume":"138","author":"Wiedermann","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1515\/acph-2015-0019","article-title":"Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment","volume":"65","author":"Liu","year":"2015","journal-title":"Acta Pharm"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.22270\/jddt.v8i6-s.2163","article-title":"Overview on virosomes as a novel carrier for drug delivery","volume":"8","author":"Shaikh","year":"2019","journal-title":"JDDT [Internet]"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1039\/C8BM00175H","article-title":"Bio-inspired drug delivery systems: an emerging platform for targeted cancer therapy","volume":"6","author":"Ngandeu Neubi","year":"2018","journal-title":"Biomater Sci"},{"key":"B182","doi-asserted-by":"publisher","first-page":"45005","DOI":"10.1088\/2057-1976\/ab89f1","article-title":"Design of an innovative platform for the treatment of cerebral tumors by means of erythro-magneto-HA-virosomes","volume":"6","author":"Lucarini","year":"2020","journal-title":"BioMed Phys Eng Express"},{"key":"B183","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s11671-017-1828-z","article-title":"The Effect of Superparamagnetic Iron Oxide Nanoparticle Surface Charge on Antigen Cross-Presentation","volume":"12","author":"Mou","year":"2017","journal-title":"Nanoscale Res Lett"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1016\/j.mattod.2017.11.022","article-title":"Metallic Nanoparticles for Cancer Immunotherapy","volume":"21","author":"Evans","year":"2018","journal-title":"Mater Today (Kidlington)"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5b02153","article-title":"Polyelectrolyte Multilayers Assembled Entirely from Immune Signals on Gold Nanoparticle Templates Promote Antigen-Specific T Cell Response","volume":"9","author":"Zhang","year":"2015","journal-title":"ACS Nano"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.msec.2017.02.132","article-title":"Carbon nanotubes: A review of novel strategies for cancer diagnosis and treatment","volume":"76","author":"Sheikhpour","year":"2017","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"B187","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jconrel.2019.01.017","article-title":"Application of carbon nanotubes in cancer vaccines: Achievements, challenges and chances","volume":"297","author":"Hassan","year":"2019","journal-title":"J Control Release"},{"key":"B188","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.eurpolymj.2019.03.009","article-title":"Polymers for subunit vaccine delivery","volume":"114","author":"Nevagi","year":"2019","journal-title":"Eur Polym J"},{"key":"B189","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-9092-4_6","article-title":"Synthesis of Polyethylenimine-Based Nanocarriers for Systemic Tumor Targeting of Nucleic Acids","volume-title":"Nanotechnology for Nucleic Acid Delivery. Methods in Molecular Biology","author":"R\u00f6dl","year":"2019"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1038\/nnano.2011.105","article-title":"Thermodynamically stable RNA three-way junctions as platform for constructing multifunctional nanoparticles for delivery of therapeutics","volume":"6","author":"Shu","year":"2011","journal-title":"Nat Nanotechnol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1038\/nature08016","article-title":"Self-assembly of DNA into nanoscale three-dimensional shapes","volume":"459","author":"Douglas","year":"2009","journal-title":"Nature"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1038\/srep05128","article-title":"Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity","volume":"4","author":"Phua","year":"2014","journal-title":"Sci Rep"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060190","article-title":"Alginic acid-coated chitosan nanoparticles loaded with legumain DNA vaccine: effect against breast cancer in mice","volume":"8","author":"Liu","year":"2013","journal-title":"PloS One"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1039\/C4PY01394H","article-title":"Microneedle-assisted dendritic cell-targeted nanoparticles for transcutaneous DNA immunization","volume":"6","author":"Hu","year":"2015","journal-title":"Polym Chem"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2010.12.010","article-title":"Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messanger RNA","volume":"7","author":"Perche","year":"2011","journal-title":"Nanomedecine"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181403","article-title":"Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T cell responses","volume":"12","author":"Carpentier","year":"2017","journal-title":"PloS One"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02631-7","article-title":"The adjuvant effect of melanin is superior to incomplete Freund\u2019s\u00a0adjuvant in subunit\/peptide vaccines in mice","volume":"69","author":"Cuzzubbo","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines3030662","article-title":"Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy","volume":"3","author":"Fan","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.03.010","article-title":"Immune system targeting by biodegradable nanoparticles for cancer vaccines","volume":"168","author":"Silva","year":"2013","journal-title":"J Control Release"},{"key":"B200","first-page":"31","article-title":"Biodegradable nanoparticles as vaccine adjuvants and delivery systems: Regulation of immune responses by nanoparticle-based vaccine. Polymers in Nanomedicine","volume-title":"Advances in Polymer Science, vol 247","author":"Akagi","year":"2011"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1021\/nn305466z","article-title":"pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides","volume":"7","author":"Wilson","year":"2013","journal-title":"ACS Nano"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1313152110","article-title":"Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose","volume":"110","author":"De Titta","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2014.03.039","article-title":"The effect of combined IL10 siRNA and CpG ODN as pathogen-mimicking microparticles on Th1\/Th2 cytokine balance in dendritic cells and protective immunity against B cell lymphoma","volume":"35","author":"Pradhan","year":"2014","journal-title":"Biomaterials"},{"key":"B204","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jconrel.2014.11.033","article-title":"In vivo delivery of peptides and Toll-like receptor ligands by mannose-functionalized polymeric nanoparticles induces prophylactic and therapeutic anti-tumor immune responses in a melanoma model","volume":"198","author":"Silva","year":"2015","journal-title":"J Control Release"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw6071","article-title":"A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer","volume":"6","author":"Ni","year":"2020","journal-title":"Sci Adv"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1021\/nn500216y","article-title":"Nanoparticle-delivered transforming growth factor-\u03b2 siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment","volume":"8","author":"Xu","year":"2014","journal-title":"ACS Nano"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2013.12.024","article-title":"Dextran derivative-based pH-sensitive liposomes for cancer immunotherapy","volume":"35","author":"Yuba","year":"2014","journal-title":"Biomaterials"},{"key":"B208","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jconrel.2014.03.041","article-title":"Neutral Neutral polymer micelle carriers with pH-responsive, endosome-releasing activity modulate antigen trafficking to enhance CD8+ T cell responses","volume":"191","author":"Keller","year":"2014","journal-title":"J\u00a0Control Release"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2012.04.060","article-title":"Dendritic cell activation and T cell priming with adjuvant-and antigen-loaded oxidation-sensitive polymersomes","volume":"33","author":"Scott","year":"2012","journal-title":"Biomaterials"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201300597","article-title":"Gold nanoparticles displaying tumor-associated self-antigens as a potential vaccine for cancer immunotherapy","volume":"3","author":"Ahn","year":"2014","journal-title":"Adv Health Mater"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1021\/mp500147y","article-title":"Octaarginine-modified liposomes enhance cross-presentation by promoting the c-terminal trimming of antigen peptide","volume":"11","author":"Nakamura","year":"2014","journal-title":"Mol Pharm"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1038\/nmat2357","article-title":"Infection-mimicking materials to program dendritic cells in situ","volume":"8","author":"Ali","year":"2009","journal-title":"Nat Mater"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2014.07.040","article-title":"Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8+ T cell response: A comparative study","volume":"192","author":"Cruz","year":"2014","journal-title":"J Control Release"},{"key":"B214","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.imlet.2014.07.004","article-title":"Targeting human dendritic cells in situ to improve vaccines","volume":"162","author":"Sehgal","year":"2014","journal-title":"Immunol Lett"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20092140","article-title":"Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens","volume":"207","author":"Jongbloed","year":"2010","journal-title":"J Exp Med"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1038\/nri3254","article-title":"Cross-presentation by dendritic cells","volume":"12","author":"Joffre","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1021\/mp400717r","article-title":"Tracking targeted bimodal nanovaccines: Immune responses and routing in cells, tissue, and whole organism","volume":"11","author":"Cruz","year":"2014","journal-title":"Mol Pharm"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.5b00109","article-title":"Synthetic nanoparticles for vaccines and immunotherapy","volume":"115","author":"Irvine","year":"2015","journal-title":"Chem Rev"},{"key":"B219","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ebiom.2016.01.029","article-title":"Functional specialty of CD40 and dendritic dell surface lectins for exogenous antigen presentation to CD8(+) and CD4(+) T cells","volume":"5","author":"Yin","year":"2016","journal-title":"EBioMedicine"},{"key":"B220","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4049\/jimmunol.1700911","article-title":"Formation of immune complexes with a tetanus-derived B cell epitope boosts human T cell responses to covalently linked peptides in an ex vivo blood loop system","volume":"201","author":"Fletcher","year":"2018","journal-title":"J Immunol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2017.11.004","article-title":"Linking T cell epitopes to a common linear B cell epitope: A targeting and adjuvant strategy to improve T cell responses","volume":"93","author":"Mangsbo","year":"2018","journal-title":"Mol Immunol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1433516","article-title":"Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I\/II trial","volume":"7","author":"Patel","year":"2018","journal-title":"Oncoimmunology"},{"key":"B223","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4161\/mabs.1.1.7492","article-title":"Antibodies designed as effective cancer vaccines","volume":"1","author":"Metheringham","year":"2009","journal-title":"MAbs"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2158-4","article-title":"Personalized cancer vaccines: adjuvants are important, too","volume":"67","author":"Gouttefangeas","year":"2018","journal-title":"Cancer Immunol Immunoth"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1602131","article-title":"Cutting edge: a dual TLR2 and TLR7 ligand induces highly potent humoral and cell-mediated immune responses","volume":"198","author":"Gutjahr","year":"2017","journal-title":"J Immunol"},{"key":"B226","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1084\/jem.20031591","article-title":"Combined TLR and CD40 triggering induces potent CD8 + T cell expansion with variable dependence on type I IFN","volume":"199","author":"Ahonen","year":"2004","journal-title":"J Exp Med"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2019","article-title":"Optimized peptide vaccines eliciting extensive CD8 T cell responses with therapeutic antitumor effects","volume":"69","author":"Cho","year":"2009","journal-title":"Cancer Res"},{"key":"B228","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2015.01.011","article-title":"Targeting the tumor vasculature to enhance T cell activity","volume":"33","author":"Lanitis","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B229","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nm1699","article-title":"Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy","volume":"14","author":"Buckanovich","year":"2008","journal-title":"Nat Med"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-1956","article-title":"VEGF inhibits T cell development and may contribute to tumor-induced immune suppression","volume":"101","author":"Ohm","year":"2003","journal-title":"Blood"},{"key":"B231","article-title":"Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function","volume":"5","author":"Gabrilovich","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B232","article-title":"All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination","volume":"63","author":"Kusmartsev","year":"2003","journal-title":"Cancer Res"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-3272","article-title":"Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer","volume":"16","author":"Nagaraj","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201142335","article-title":"Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T cell responses","volume":"42","author":"Sumida","year":"2012","journal-title":"Eur J Immunol"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1172\/JCI58814","article-title":"IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors","volume":"121","author":"Kerkar","year":"2011","journal-title":"J Clin Invest"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-237412","article-title":"Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy","volume":"115","author":"Priceman","year":"2010","journal-title":"Blood"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-012-9869-8","article-title":"Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer","volume":"31","author":"Pienta","year":"2013","journal-title":"Invest New Drugs"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0671-1","article-title":"Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model","volume":"58","author":"Banissi","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"B240","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00262-013-1397-7","article-title":"Effects of cyclophosphamide and IL-2 on regulatory CD4+ T-cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T-cell response","volume":"62","author":"Camisaschi","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B241","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.clim.2016.03.015","article-title":"Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors","author":"Murahashi","year":"2016","journal-title":"Clin Immunol"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-67577-0_8","article-title":"Targeting myeloid-derived suppressor cells in cancer","volume":"1036","author":"Anani","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0733","article-title":"A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers","volume":"16","author":"Kodumudi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"B245","article-title":"Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte\/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2\/neu tolerized mice","volume":"61","author":"Machiels","year":"2001","journal-title":"Cancer Res"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-88","article-title":"HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial","volume":"11","author":"van Poelgeest","year":"2013","journal-title":"J Transl Med"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2013","article-title":"Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer","volume":"12","author":"Antonia","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0749-9","article-title":"The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy","volume":"59","author":"Wu","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf0746","article-title":"Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T-cell responses","volume":"8","author":"Welters","year":"2016","journal-title":"Sci Transl Med"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-015-1698-0","article-title":"Novel metronomic chemotherapy and cancer vaccine combinatorial strategy for hepatocellular carcinoma in a mouse model","volume":"64","author":"Tagliamonte","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.3747\/co.27.5223","article-title":"A review of cancer immunotherapy: from the past, to the present, to the future","volume":"27","author":"Esfahani","year":"2020","journal-title":"Curr Oncol"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27745","article-title":"CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells","volume":"116","author":"Quezada","year":"2006","journal-title":"J Clin Invest"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2564","article-title":"Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody","volume":"74","author":"Karyampudi","year":"2014","journal-title":"Cancer Res"},{"key":"B254","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0000000000000062","article-title":"PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T cell infiltration into pancreatic tumors","volume":"38","author":"Soares","year":"2015","journal-title":"J Immunother"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1514418112","article-title":"Unique potential of 4-1BB ag-onist antibody to promote durable regression of HPV+ tumors when combined with an E6\/E7 peptide vaccine","volume":"112","author":"Bartkowiak","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"B256","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00281-018-0691-z","article-title":"Therapeutic cancer vaccine: building the future from lessons of the past","volume":"41","author":"Tran","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B257","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00088","article-title":"The convergence of radiation and immunogenic cell death signaling pathways","volume":"2","author":"Golden","year":"2012","journal-title":"Front Oncol"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J Exp Med"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.12.6338","article-title":"Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy","volume":"170","author":"Chakraborty","year":"2003","journal-title":"J Immunol"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0073","article-title":"External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T cell killing","volume":"64","author":"Chakraborty","year":"2004","journal-title":"Cancer Res"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.06.032","article-title":"Combining radiotherapy and immunotherapy: a revived partnership","volume":"63","author":"Demaria","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv209","article-title":"Combining immunotherapy and anticancer agents: the right path to achieve cancer cure","volume":"26","author":"Apetoh","year":"2015","journal-title":"Ann Oncol"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2824","article-title":"Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions","volume":"21","author":"Filatenkov","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-1015","article-title":"Synergy of radiotherapy and a cancer vaccine for the treatment of HPV-associated head and neck Cancer","volume":"14","author":"Mondini","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.10.1555","article-title":"CD4(+) T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells","volume":"187","author":"Adler","year":"1998","journal-title":"J Exp Med"},{"key":"B269","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/imt-2017-0082","article-title":"Radiation therapy and immunotherapy: what is the optimal timing or sequencing","volume":"10","author":"Aliru","year":"2018","journal-title":"Immunotherapy"},{"key":"B270","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","article-title":"Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma","volume":"7","author":"Zheng","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B271","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"et.al., Gut microbiome modulates response to anti\u2013PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.27224","article-title":"Probiotic bacteria enhance murine and human intestinal epithelial barrier function","volume":"121","author":"Madsen","year":"2001","journal-title":"Gastroenterology"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804812105","article-title":"Faecali bacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients","volume":"105","author":"Sokol","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1126\/science.1110591","article-title":"Diversity of the human intestinal microbial flora","volume":"308","author":"Eckburg","year":"2005","journal-title":"Science"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.08.009","article-title":"TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination","volume":"41","author":"Oh","year":"2014","journal-title":"Immunity"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209153","article-title":"A microbial-based cancer vaccine for induction of EGFRvIII-specific CD8+ T cells and anti-tumor immunity","volume":"14","author":"Zebertavage","year":"2019","journal-title":"PloS One"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2325","article-title":"Mechanisms linking physical activity with cancer","volume":"8","author":"McTiernan","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B280","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs207","article-title":"Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review","volume":"104","author":"Ballard-Barbash","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.01.011","article-title":"Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution","volume":"23","author":"Pedersen","year":"2016","journal-title":"Cell Metab"},{"key":"B282","first-page":"8","article-title":"Human natural killer cell subsets and acute exercise: a brief review","volume":"14","author":"Timmons","year":"2008","journal-title":"Exerc Immunol Rev"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-2952(96)00904-5","article-title":"Apoptotic death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors","volume":"53","author":"McBain","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4400935","article-title":"Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria","volume":"9","author":"Jan","year":"2002","journal-title":"Cell Death Differ"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2016.1144879","article-title":"Butyrate production from high-fiber diet protects against lymphoma tumor","volume":"57","author":"Wei","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20051971","article-title":"A fundamental bimodal role for neuropeptide Y1 receptor in the immune system","volume":"202","author":"Wheway","year":"2005","journal-title":"J Exp Med"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.580378","article-title":"Neuropeptide Y Is an Immunomodulatory Factor: Direct and Indirect","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1266-9","article-title":"Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma","volume":"61","author":"Becker","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.11.036","article-title":"Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C)","volume":"29","author":"Wick","year":"2011","journal-title":"Vaccine"},{"key":"B290","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines4040044","article-title":"Homologous Prime-Boost Vaccination with OVA Entrapped in Self-Adjuvanting Archaeosomes Induces High Numbers of OVA-Specific CD8+ T Cells that Protect Against Subcutaneous B16-OVA Melanoma","volume":"4","author":"Stark","year":"2016","journal-title":"Vaccines (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.615240\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T06:22:05Z","timestamp":1613802125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.615240\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":290,"alternative-id":["10.3389\/fimmu.2020.615240"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.615240","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"article-number":"615240"}}